anagrama

We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of the LRKK2 gene and reduce the formation of alfasynuclein.

Compartir:
CategoryParkinson

© 2022–2026 - UDIC - Unitat d'Investigació Clínica, SL · Soporte técnico